Dr. Heidi A. McKean, MD | Sioux Falls ...

Dr. Heidi McKean

Claim this profile

Avera Cancer Institute

Studies Colorectal Cancer
Studies Pancreatic Cancer
10 reported clinical trials
26 drugs studied

Area of expertise

1Colorectal Cancer
Heidi McKean has run 4 trials for Colorectal Cancer. Some of their research focus areas include:
Stage III
Stage IV
HER2 positive
2Pancreatic Cancer
Heidi McKean has run 3 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive

Affiliated Hospitals

Image of trial facility.
Avera Cancer Institute
Image of trial facility.
Avera Cancer Institute-Aberdeen

Clinical Trials Heidi McKean is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Tucatinib + Trastuzumab + Chemotherapy

for Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3

More about Heidi McKean

Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Heidi McKean has experience with
  • Oxaliplatin
  • MFOLFIRINOX
  • Fluorouracil
  • Olaparib
  • Irinotecan
  • CAPOX

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Heidi McKean specialize in?
Is Heidi McKean currently recruiting for clinical trials?
Are there any treatments that Heidi McKean has studied deeply?
What is the best way to schedule an appointment with Heidi McKean?
What is the office address of Heidi McKean?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security